obesity program drives stock outlook By Investing.com
Amgen Inc . (NASDAQ:), a leading biopharmaceutical company with a market capitalization of $145.47 billion, has been garnering significant attention from analysts and investors alike as it continues to make strides in its diverse product portfolio and promising pipeline. According to InvestingPro data, the company maintains a strong financial health score and has demonstrated impressive revenue growth of 21.25% over the last twelve months. The company’s focus on innovative therapeutics, particularly in the obesity treatment market, has positioned it as a potential major player in the rapidly expanding field of cardiometabolic medicine.
Recent Financial Performance and Outlook
In the second quarter of 2024, Amgen reported in-line…
